Horizon Discovery plc Proprietà istituzionale
Cos'è Proprietà istituzionale di Horizon Discovery plc?
Proprietà istituzionale di Horizon Discovery Group plc è 59.19%
Qual è la definizione di Proprietà istituzionale?
Proprietà istituzionale (Institutional Ownership) è la quantità di azioni disponibili di una società di proprietà di fondi comuni o pensionistici, compagnie assicurative, società di investimento, fondi o altre grandi entità che gestiscono fondi per conto di terzi.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
Proprietà istituzionale di aziende nel Health Care settore su LSE rispetto a Horizon Discovery plc
Cosa fa Horizon Discovery plc?
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Aziende con proprietà istituzionale simili a Horizon Discovery plc
- TKH NV ha Proprietà istituzionale di 59.03%
- JD Wetherspoon Plc ha Proprietà istituzionale di 59.03%
- Schroder Real Estate Investment Trust ha Proprietà istituzionale di 59.05%
- Farmer Bros. Co ha Proprietà istituzionale di 59.08%
- Lakeland ha Proprietà istituzionale di 59.08%
- Renewi Plc ha Proprietà istituzionale di 59.15%
- Horizon Discovery plc ha Proprietà istituzionale di 59.19%
- Foghorn Therapeutics ha Proprietà istituzionale di 59.20%
- Lightspeed POS ha Proprietà istituzionale di 59.21%
- Empiric Student Property PLC ha Proprietà istituzionale di 59.26%
- China Industrial Securities International ha Proprietà istituzionale di 59.26%
- Peridot Acquisition ha Proprietà istituzionale di 59.27%
- CTO Realty Growth Inc ha Proprietà istituzionale di 59.27%